Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016
Open Access
- 14 February 2019
- journal article
- review article
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 24 (7), 1700857-20
- https://doi.org/10.2807/1560-7917.es.2019.24.7.1700857
Abstract
Introduction: Although human papillomavirus (HPV) routine vaccination programmes have been implemented around the world and recommendations have been expanded to include other high-risk individuals, current recommendations often differ between countries in Europe, as well as worldwide. Aim: To find and summarise the best available evidence of HPV vaccination in high-risk patients aiding clinicians and public health workers in the day-to-day vaccine decisions relating to HPV in Spain. Methods: We conducted a systematic review of the immunogenicity, safety and efficacy/effectiveness of HPV vaccination in high-risk populations between January 2006 and June 2016. HPV vaccination recommendations were established with levels of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Results: A strong recommendation about HPV vaccination was made in the following groups: HIV infected patients aged 9–26 years; men who have sex with men aged 9–26 years; women with precancerous cervical lesions; patients with congenital bone marrow failure syndrome; women who have received a solid organ transplant or hematopoietic stem cell transplantation aged 9–26 years; and patients diagnosed with recurrent respiratory papillomatosis. Conclusions: Data concerning non-routine HPV vaccination in populations with a high risk of HPV infection and associated lesions were scarce. We have developed a document to evaluate and establish evidence-based guidelines on HPV vaccination in high-risk populations in Spain, based on best available scientific evidence.Keywords
This publication has 118 references indexed in Scilit:
- GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendationsJournal of Clinical Epidemiology, 2013
- Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North AmericaClinical Infectious Diseases, 2012
- HPV Vaccine against Anal HPV Infection and Anal Intraepithelial NeoplasiaThe New England Journal of Medicine, 2011
- End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of ageBritish Journal of Cancer, 2011
- High-risk human papillomavirus in non-melanoma skin lesions from renal allograft recipients and immunocompetent patientsBritish Journal of Cancer, 2011
- Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in MalesThe New England Journal of Medicine, 2011
- Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV‐1–Infected MenThe Journal of Infectious Diseases, 2010
- Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years OldJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Tumor necrosis factor blockade and the risk of viral infectionNature Reviews Rheumatology, 2010
- Increased Risk of Cervical Dysplasia in Long-Term Survivors of Allogeneic Stem Cell Transplantation—Implications for Screening and HPV VaccinationTransplantation and Cellular Therapy, 2008